Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MARION CARDIZEM SR INITIAL SELL-IN GENERATES $ 19 MIL. SALES

Executive Summary

MARION CARDIZEM SR INITIAL SELL-IN GENERATES $ 19 MIL. SALES following the launch of the b.i.d-sustained release form of the calcium channel blocker in March, Marion Senior Exec VP James McGraw told an Alex. Brown healthcare seminar in Baltimore May 10. Cardizem SR (manufactured for Marion by the Elan Corporation and licensed from Tanabe) was approved by FDA on Jan. 24 for the treatment of hypertension. Marion plans to file for a once-a-day formulation of Cardizem SR "in the near future," McGraw said. Once approved, the new formulation will give Cardizem an additional three years of exclusivity beyond its November 1992 patent expiration date, McGraw noted. The immediate release form of Cardizem (diltiazem), which is indicated for angina, generated fiscal 1988 (ended June 30) sales of $ 442 mil. Through nine months of fiscal 1989, sales have reached $ 410 mil. and the drug is being prescribed at the rate of 1 mil. new prescriptions per month, McGraw said. Sales of the antiulcer drug Carafate (sucralfate) reached $ 140 mil. after nine months. Marion is predicting that full year sales will top $ 200 mil. FDA is currently reviewing a suspension form of the drug, which Marion expects will be approved in fiscal 1990 or fiscal 1991. By that time, an OTC form of Carafate also may be ready, McGraw indicated. He also predicted that FY 1992 would see the FDA approval of Pentasa for Crohn's disease and ulcerative colitis. Pentasa (5-amino-salicylic acid) is licensed by Marion from the Danish firm Ferring. Marion sales are expected to reach more than $ 900 mil. in fiscal 1989, a 25-30% increase over the previous year, the Marion exec reported. Sales of two OTCs, Os-cal and Gaviscon, combined have already topped the $ 100 mil. sales level so far this year.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel